(Q36505465)

14 August 2017

1 reference

title

Pharmacogenetic issues in thorough QT trials (English)

1 reference

14 August 2017

4

Michael J Ackerman

1 reference

14 August 2017

Richard S Judson

1

1 reference

14 August 2017

Benjamin A Salisbury

series ordinal

2

1 reference

14 August 2017

Carol R Reed

series ordinal

3

1 reference

14 August 2017

publication date

1 January 2006

1 reference

Molecular Diagnosis and Therapy

14 August 2017

published in

1 reference

14 August 2017

volume

10

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

153-162

1 reference

Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Cardiac channelopathies: it's in the genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Risk stratification in the long-QT syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

QT interval: a measure of drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Drug-induced prolongation of the QT interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

In vitro and in vivo drug interactions involving human CYP3A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Food-drug interactions via human cytochrome P450 3A (CYP3A).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Use of terfenadine and contraindicated drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Concomitant use of antipsychotics and drugs that may prolong the QT interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Exploring the hidden danger of noncardiac drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Genetic defects of cardiac ion channels. The hidden substrate for torsades de pointes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

A common polymorphism associated with antibiotic-induced cardiac arrhythmia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

DHPLC analysis of potassium ion channel genes in congenital long QT syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Molecular determinants of KCNQ1 channel block by a benzodiazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Stilbenes and fenamates rescue the loss of I(KS) channel function induced by an LQT5 mutation and other IsK mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

A structural basis for drug-induced long QT syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Interaction with GM130 during HERG ion channel trafficking. Disruption by type 2 congenital long QT syndrome mutations. Human Ether-à-go-go-Related Gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsades de Pointes in models of acquired and congenital long QT syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Molecular and cellular mechanisms of cardiac arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Characteristics of the delayed rectifier current (IKr and IKs) in canine ventricular epicardial, midmyocardial, and endocardial myocytes. A weaker IKs contributes to the longer action potential of the M cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Requirement of a macromolecular signaling complex for beta adrenergic receptor modulation of the KCNQ1-KCNE1 potassium channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Drug-induced QT prolongation in women during the menstrual cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Gender and the relationship between ventricular repolarization and cardiac cycle length during 24-h Holter recordings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. LQTS Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Identification of a common genetic substrate underlying postpartum cardiac events in congenital long QT syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Gender differences in heart rate before and after autonomic blockade: evidence against an intrinsic gender effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256454

Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing

21 January 2018

1 reference

12 December 2020

Low penetrance in the long-QT syndrome: clinical impact

1 reference

12 December 2020

A founder mutation of the potassium channel KCNQ1 in long QT syndrome: implications for estimation of disease prevalence and molecular diagnostics

1 reference

12 December 2020

Delayed repolarization (QT or QTU prolongation) and malignant ventricular arrhythmias

1 reference

12 December 2020

Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome

1 reference

12 December 2020

Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites.

1 reference

12 December 2020

The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome. Tridimensional mapping of activation and recovery patterns

1 reference

12 December 2020

Taking the "idio" out of "idiosyncratic": predicting torsades de pointes

1 reference

12 December 2020

Coprescription of terfenadine and erythromycin or ketaconazole: an assessment of potential harm

1 reference

12 December 2020

Effects of gonadal steroids on ventricular repolarization and on the response to E4031.

1 reference

12 December 2020

Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients

1 reference

12 December 2020

Compound mutations: a common cause of severe long-QT syndrome

1 reference

12 December 2020

Polymorphisms in beta-adrenergic receptor genes in the acquired long QT syndrome

1 reference

12 December 2020

Torsades de pointes occurring in association with terfenadine use

1 reference

12 December 2020

Mechanism of arrhythmogenicity of the short-long cardiac sequence that precedes ventricular tachyarrhythmias in the long QT syndrome

1 reference

12 December 2020

KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome

1 reference

12 December 2020

1 reference

12 December 2020

Blockade of HERG channels by HIV protease inhibitors.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03256454

1 reference

14 August 2017

1 reference